Clinical Trial Update: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of XmAb18968 (CD3-CD38) in relapsed or refractory acute myeloid leukemia and T-cell lymphoblastic leukemia/lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• XmAb18968 (CD3-CD38) (CD3-CD38 bispecific antibody)

Snippet

Sponsor: Ehab L Atallah | Conditions: Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED